• 1
    Arendrup MC, Bruun B, Christensen JJ et al. National Surveillance of Fungemia in Denmark 2004–2009. J Clin Microbiol 2011; 49: 325334.
  • 2
    Boo TW, O'Reilly B, O'Leary J, Cryan B. Candidaemia in an Irish tertiary referral hospital: epidemiology and prognostic factors. Mycoses 2005; 48: 251259.
  • 3
    Playford EG, Nimmo GR, Tilse M, Sorrell TC. Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999–2008. J Hosp Infect 2010; 76: 4651.
  • 4
    Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S. Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother 2005; 56: 532537.
  • 5
    Cleveland AA, Farley MM, Harrison LH et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clin Infect Dis 2012; 55: 13521361.
  • 6
    Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 36403645.
  • 7
    Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 2531.
  • 8
    Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002; 40: 34893492.
  • 9
    Leon C, Ruiz-Santana S, Saavedra P et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34: 730737.
  • 10
    Leon CM, Ruiz-Santana SMP, Saavedra PP et al. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009; 37: 16241633.
  • 11
    Manzoni P, Leonessa M, Galletto P et al. Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr Infect Dis J 2008; 27: 731737.
  • 12
    Playford EG, Lipman J, Kabir M et al. Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients. Intensive Care Med 2009; 35: 21412145.
  • 13
    Leroy G, Lambiotte F, Thevenin D et al. Evaluation of “Candida score” in critically ill patients: a prospective, multicenter, observational, cohort study. Ann Intensive Care 2011; 1: 50.
  • 14
    Ostrosky-Zeichner L, Pappas PG, Shoham S et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 2011; 54: 4651.
  • 15
    Maertens J, Marchetti O, Herbrecht R et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 Update. Bone Marrow Transplant 2011; 46: 709718.
  • 16
    Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503535.
  • 17
    Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care 2010; 16: 445452.
  • 18
    Arendrup MC, Sulim S, Holm A et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol 2011; 49: 33003308.
  • 19
    Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011; 55: 532538.
  • 20
    Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008; 56: 126129.
  • 21
    Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115: 47454752.
  • 22
    Nordøy I, Gaustad P, Sandven P. Norwegian Yeast Study Group Candidaemia in Norway. Mycoses 2009; 52(Suppl. 1): 43.
  • 23
    Poikonen E, Lyytikainen O, Anttila VJ et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004–2007. BMC Infect Dis 2010; 10: 312.
  • 24
    Arendrup MC, Fuursted K, Gahrn-Hansen B et al. Semi-national surveillance of fungaemia in Denmark 2004–2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 2008; 14: 487494.
  • 25
    Klingspor L, Tornqvist E, Johansson A, Petrini B, Forsum U, Hedin G. A prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis 2004; 36: 5255.
  • 26
    Kibbler CC, Seaton S, Barnes RA et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 2003; 54: 1824.
  • 27
    Swinne D, Watelle M, Suetens C, Mertens K, Fonteyne PA, Nolard N. A one-year survey of candidemia in Belgium in 2002. Epidemiol Infect 2004; 132: 11751180.
  • 28
    Sendid B, Cotteau A, Francois N et al. Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infect Dis 2006; 6: 80.
  • 29
    Almirante B, Rodriguez D, Park BJ et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 18291835.
  • 30
    Odds FC, Hanson MF, Davidson AD et al. One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 2007; 56: 10661075.
  • 31
    Presterl E, Daxbock F, Graninger W, Willinger B. Changing pattern of candidaemia 2001–2006 and use of antifungal therapy at the University Hospital of Vienna, Austria. Clin Microbiol Infect 2007; 13: 10721076.
  • 32
    Tortorano AM, Biraghi E, Astolfi A et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J Hosp Infect 2002; 51: 297304.
  • 33
    Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010; 48: 23732380.
  • 34
    Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50: 11991203.
  • 35
    Zimbeck AJ, Iqbal N, Ahlquist AM et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother 2010; 54: 50425047.
  • 36
    Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006; 42: 938944.
  • 37
    Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D et al. Candida spp. with acquired echinocandin resistance, France, 2004–2010. Emerg Infect Dis 2012; 18: 8690.
  • 38
    Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 15191527.
  • 39
    Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsaker T, Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 2006; 44: 19771981.
  • 40
    Peman J, Canton E, Gobernado M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 2005; 24: 2330.
  • 41
    Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006; 27: 359366.
  • 42
    Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133163.
  • 43
    Arendrup MC, Fuursted K, Gahrn-Hansen B et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 2005; 43: 44344440.
  • 44
    Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope W. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect 2012; 18: E246E247.
  • 45
    Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard, 3rd edn. CLSI document M27-A3[28]. Pennsylvania, USA: Clinical and laboratory Standards Institute, 2008.
  • 46
    Arendrup MC, Rodriguez-Tudela JL, Lass-Flörl C et al. EUCAST technical note on anidulafungin. Clin Microbiol Infect 2011; 17: E18E20.
  • 47
    Pfaller MA, Diekema DJ, Andes D et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14: 164176.
  • 48
    European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST Technical Note on fluconazole. Clin Microbiol Infect 2008; 14: 193195.
  • 49
    Arendrup MC, Cuenca-Estrella M, Donnelly JP et al. EUCAST Technical Note on posaconazole*. Clin Microbiol Infect 2011; 17: E16E17.
  • 50
    Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST Technical Note on voriconazole. Clin Microbiol Infect 2008; 14: 985987.
  • 51
    Brillowska-Dabrowska A, Saunte DM, Arendrup MC. Five-hour diagnosis of dermatophyte nail infections with specific detection of Trichophyton rubrum. J Clin Microbiol 2007; 45: 12001204.
  • 52
    Arendrup MC, Garcia-Effron G, Lass-Florl C et al. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27–A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother 2010; 54: 426439.
  • 53
    Poikonen E, Lyytikainen O, Anttila VJ, Ruutu P. Candidemia in Finland, 1995–1999. Emerg Infect Dis 2003; 9: 985990.
  • 54
    Arendrup MC, Pfaller MA. Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob Agents Chemother 2012; 56: 39653968.
  • 55
    Jensen RH, Johansen HK, Arendrup MC. Stepwise development of homozygous S80P substitution in Fks1p conferring echinocandin resistance in Candida tropicalis. Antimicrob Agents Chemother 2013; 57: 614617.
  • 56
    Horvath LL, George BJ, Murray CK, Harrison LS, Hospenthal DR. Direct comparison of the BACTEC 9240 and BacT/ALERT 3D automated blood culture systems for Candida growth detection. J Clin Microbiol 2004; 42: 115118.
  • 57
    Andes DR, Safdar N, Baddley JW et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54: 11101122.
  • 58
    Cuenca-Estrella M, Verweij PE, Arendrup MC et al. for the ESCMID Fungal Infection Study Group (EFISG) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 2012; 2012(18): 918.
  • 59
    Cornely OA, Bassetti M, Calandra T et al. ESCMID* Guideline for the Diagnosis and Management of Candida Diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18: 1937.
  • 60
    Ullmann AJ, Akova M, Herbrecht R et al. ESCMID* Guideline for the Diagnosis and Management of Candida Diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012; 18: 5367.
  • 61
    Ullmann AJ, Cornely OA, Peter Donnelly J et al. for the ESCMID Fungal Infection Study Group (EFISG) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect 2012; 2012(18): 18.
  • 62
    Lortholary O, Petrikkos G, Akova M et al. ESCMID* Guideline for the Diagnosis and Management of Candida Diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect 2012; 18: 6877.
  • 63
    Hope WW, Castagnola E, Groll AH et al. ESCMID* guideline for the diagnosis and management of Candida Diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012; 18: 3852.
  • 64
    Brillowska-Dabrowska A, Bergmann O, Jensen IM, Jarlov JO, Arendrup MC. Typing of Candida isolates from patients with invasive infection and concomitant colonization. Scand J Infect Dis 2010; 42: 109113.
  • 65
    Arendrup MC, Garcia-Effron G, Buzina W et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother 2009; 53: 11851193.
  • 66
    Baixench MT, Aoun N, Desnos-Ollivier M et al. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 2007; 59: 10761083.
  • 67
    Shields RK, Nguyen MH, Press EG et al. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive Candidiasis due to Candida glabrata. Antimicrob Agents Chemother 2012; 56: 48624869.
  • 68
    Oxman DA, Chow JK, Frendl G et al. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J Antimicrob Chemother 2010; 65: 14601465.
  • 69
    Cuenca-Estrella M, Gomez-Lopez A, Cuesta I, Zaragoza O, Mellado E, Rodriguez-Tudela JL. Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. according to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2011; 55: 17941797.